Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
Rhea-AI Summary
Skye Bioscience (Nasdaq: SKYE) reported Q1 2026 results and advanced its nimacimab obesity program.
Cash, equivalents and short-term investments were $17.1 million, expected to fund operations and key milestones through Q4 2026, excluding proposed Phase 2b clinical and additional manufacturing costs.
CBeyond™ Part C began, with topline data expected in Q4 2026, and prior data showed an approximately 3% incremental weight-loss benefit and 22.3% mean weight loss for nimacimab plus semaglutide, with favorable tolerability. Q1 R&D expenses were $7.9 million, G&A $4.7 million, and net loss $12.5 million.
AI-generated analysis. Not financial advice.
Positive
- Cash, equivalents and short-term investments of $17.1 million at March 31, 2026
- Capital expected to fund operations and milestones through Q4 2026 (excluding Phase 2b costs)
- Previously reported 22.3% mean weight loss with nimacimab 200 mg plus semaglutide 2.4 mg at 52 weeks
- Approximately 3% incremental weight-loss benefit versus semaglutide alone at 26 weeks
- No observed nimacimab-associated neuropsychiatric signal and no additive gastrointestinal burden at tested dose
- Completion of all Q1 2026 clinical milestones, including launch of CBeyond Expansion Study (Part C)
- Topline CBeyond Expansion Study data anticipated in Q4 2026, providing higher-exposure safety and PK
- Engagement of Lilly Catalyze360 to advise on nimacimab target product profile and Phase 2b design
- Compatibility and in-use study completed with Halozyme’s ENHANZE to enable high-volume SC dosing
Negative
- Q1 2026 net loss of $12.5 million, up from $11.1 million in Q1 2025
- Q1 2026 R&D expenses increased to $7.9 million from $7.2 million year over year
- Q1 2026 G&A expenses increased to $4.7 million from $4.6 million year over year
- Current capital coverage through Q4 2026 excludes proposed Phase 2b clinical and additional manufacturing costs
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves: AVTX (-5.15%), FBRX (-7.44%), HURA (-1.65%) are down while CRDF (+1.86%) and ZURA (+8.37%) are up, pointing to stock-specific trading for SKYE.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 10 | Earnings & update | Positive | -9.7% | Q4 2025 results with nimacimab data and cash of $25.7M funding into Q4 2026. |
| Nov 10 | Earnings & obesity data | Positive | +2.8% | Q3 2025 results plus CBeyond data showing added weight loss versus semaglutide. |
| Aug 07 | Quarterly results | Positive | -0.8% | Q2 2025 financials with nimacimab timelines and $48.6M cash funding into Q1 2027. |
| May 08 | Q1 results | Positive | +1.1% | Q1 2025 financials and nimacimab preclinical obesity data with strong weight loss. |
| Mar 20 | Full-year results | Positive | +19.1% | 2024 results, CBeyond enrollment completion, and $68.4M cash with extended runway. |
Earnings and business updates have produced mixed reactions, with roughly half of past events selling off despite generally constructive clinical and cash runway commentary.
Over the last several earnings cycles, Skye has consistently paired financial updates with progress on nimacimab. Prior releases highlighted advancing from Phase 2a into higher-dose expansion, strong 22.3% weight-loss data in combination cohorts, and cash balances ranging from $68.4M at year-end 2024 to $25.7M at year-end 2025, funding operations into 2027 or Q4 2026. Today’s Q1 2026 report continues this pattern, updating cash, operating expenses, and timelines toward a planned Phase 2b obesity study.
Historical Comparison
In the past five earnings updates, SKYE’s average one-day move was about 2.49%, indicating typically modest reactions to financial and clinical progress news.
Across earnings updates, Skye has moved from completing Phase 2a enrollment and building cash of $68.4M, through multiple quarters of nimacimab obesity data, into higher-dose expansion and Phase 2b planning, while cash levels declined as development spending increased.
Market Pulse Summary
This announcement combines Q1 2026 financials with a detailed nimacimab development update. Skye reported cash of $17.1M, R&D expenses of $7.9M, G&A of $4.7M, and a net loss of $12.5M, while progressing the CBeyond higher-dose expansion toward topline data in Q4 2026. Investors may track cash runway, enrollment across Cohorts 1 and 2, and plans for a Phase 2b obesity study leveraging the prior 22.3% weight-loss data.
Key Terms
phase 2b medical
pharmacokinetic medical
subcutaneous medical
placebo medical
g-protein-coupled receptors medical
AI-generated analysis. Not financial advice.
- CBeyond™ Expansion Study (Part C) initiated; Cohort Review Committee review scheduled for May 18, 2026, to evaluate available safety data and potential progression to Cohort 2
- Engaged Lilly Catalyze360 to provide strategic guidance on nimacimab TPP and Phase 2b trial design
SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye” or the “Company”), a clinical stage biotechnology company developing next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related conditions, today reported financial results for the first quarter ended March 31, 2026, along with recent business updates and anticipated milestones.
“Since our March update, execution has focused on turning CBeyond into a Phase 2b-ready development program,” said Punit Dhillon, President & CEO of Skye. “We have now initiated enrollment of Cohort 1 of the CBeyond Expansion Study, executed the compatibility and in-use study with ENHANZE to support a practical high-volume subcutaneous approach, and engaged external development advisors to help pressure-test our target product profile, dose-selection rationale and Phase 2b trial design. Our objective in 2026 remains focused on defining the dose and exposure that can support a larger Phase 2b study evaluating nimacimab as a complementary add-on approach for GLP-1-experienced patients.”
Business and Clinical Highlights
CBeyondTM Expansion Study (Part C)
- Cohort 1 is designed to evaluate nimacimab 400 mg IV (equivalent to ~700 mg SC) once weekly versus matched placebo, randomized 3:1, over a 16-week treatment period followed by 12 weeks of follow-up.
- The Cohort Review Committee (CRC) is scheduled to meet on May 18, 2026 to review available Cohort 1 safety data and determine whether safe-to-proceed criteria have been met to initiate enrollment in Cohort 2.
- Cohort 2 is designed to evaluate nimacimab 600 mg IV (equivalent to ~1000 mg SC) once weekly versus matched placebo, randomized 3:1, over the same treatment and follow-up period.
- Skye continues to expect topline clinical data from the CBeyond Expansion Study in Q4 2026. The study is designed to generate higher-exposure human safety and pharmacokinetic data to inform dose selection for a planned Phase 2b study.
Q1 Accomplishments
- Skye has completed all previously announced clinical milestones for Q1: reported CBeyond interim extension data, received FDA Type C meeting minutes, launched the CBeyond Expansion Study (Part C), and completed a compatibility and in-use stability study with ENHANZE.
- The Company remains on track to complete the Q2 2026 catalyst set, including initiation of Cohort 2 enrollment, pending receipt of the CRC’s determination that safe-to-proceed criteria have been met, completion of enrollment across Cohorts 1 and 2, presentation or disclosure of additional preclinical bioconjugation data, and completion of feasibility work for the high-concentration nimacimab program.
Clinical Data Foundation Supporting the Current Development Strategy
- In previously reported CBeyond data, nimacimab plus semaglutide demonstrated an approximately
3% incremental weight-loss benefit versus semaglutide alone at 26 weeks, with statistically significant improvements in waist circumference and lean-to-fat mass ratio. - In the previously reported interim 52-week combination update, participants receiving nimacimab 200 mg plus semaglutide 2.4 mg achieved
22.3% mean weight loss, with no plateau observed at the time of analysis. - At the tested dose, nimacimab demonstrated a favorable tolerability profile, with no nimacimab-associated neuropsychiatric safety signal observed and no additive gastrointestinal adverse-event burden when combined with semaglutide.
- During off-therapy follow-up, the nimacimab plus semaglutide cohort demonstrated lower weight regain than the semaglutide-alone cohort, and available body-composition data suggested maintenance of fat-mass loss and improvement in lean-to-fat mass ratio during follow-up.
- Skye believes these findings support development of nimacimab as complementary to, rather than competitive with, incretin therapies, particularly for GLP-1-experienced patients who plateau, require additional weight loss, are titration-limited, or need more durable metabolic control.
Phase 2b Planning
- Skye has received written FDA Type C meeting minutes and is incorporating feedback into ongoing Phase 2b planning, including dose, duration, endpoints, inclusion/exclusion criteria and a defined indication and patient population for nimacimab as an add-on therapy to incretins.
- Skye has engaged Lilly Catalyze360 in a development consulting engagement to provide written feedback on the nimacimab target product profile, and Phase 2b trial architecture.
- This engagement is a development advisory engagement and does not constitute a commitment regarding any future transaction, therapeutic interest, exclusivity or corporate business development process.
CMC and Drug Delivery Strategy
- Skye has executed the compatibility and in-use study with Halozyme’s ENHANZE® (rHuPH20) technology to support a planned site-based “mix-and-deliver” approach for high-volume subcutaneous administration of nimacimab in future clinical development.
- Co-formulation with ENHANZE is intended to support practical subcutaneous delivery of higher nimacimab doses.
- Skye continues feasibility work on a high-concentration nimacimab formulation, with the objective of reducing injection volume and supporting patient-friendly subcutaneous administration across potential dose levels.
- Skye continues to evaluate manufacturing process improvements, supply-chain options and cost-of-goods levers to support late-stage development and potential commercial scalability if nimacimab is approved.
Upcoming Anticipated Milestones
- Q2 2026: Cohort Review Committee review of available Cohort 1 safety data and potential initiation of Cohort 2 enrollment.
- Q2 2026: Complete enrollment across CBeyond Expansion Study Cohorts 1 and 2.
- Q2 2026: Complete feasibility work for the high-concentration nimacimab formulation program.
- Q4 2026: Report topline clinical data from the CBeyond Expansion Study.
- Q4 2026: Finalize planned Phase 2b study design, including dose-selection rationale, protocol architecture and operational readiness plan.
First Quarter 2026 Financial Results:
Balance Sheet and Cash Flow Highlights
- Cash, cash equivalents and short-term investments totaled
$17.1 million as of March 31, 2026. The Company expects its current capital to fund projected operations and key clinical milestones through the fourth quarter of 2026, including completion of its Phase 2a extension study for nimacimab and initial manufacturing to enable the anticipated Phase 2b clinical study, but excluding the anticipated clinical cost of a proposed Phase 2b clinical study and additional anticipated drug manufacturing costs to supply any such Phase 2b study.
Operating Results
- R&D Expenses
Research and development (R&D) expenses for the three months ended March 31, 2026, were$7.9 million , as compared to$7.2 million for the same period in 2025. The increase was primarily due to contract manufacturing, clinical trial costs associated with our clinical study for nimacimab, discovery research and development expenses, salaries and stock-based compensation expense, and consulting advisory and professional fees.
- G&A Expenses
General and administrative (G&A) expenses for the three months ended March 31, 2026, were$4.7 million , as compared to$4.6 million for the same period in 2025. The increase was primarily related to increased legal fees, partially offset by decreases in investor relations, marketing and communications expenses, salaries, benefits and other direct employee related costs, and consulting, advisory and professional fees.
- Net Loss
Net loss for the three months ended March 31, 2026, totaled$12.5 million , with non-cash stock-based compensation expense of$1.5 million , compared to$11.1 million for the same period in 2025, with non-cash stock-based compensation expense of$2.2 million .
ABOUT SKYE BIOSCIENCE
Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2a clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: www.skyebioscience.com. Connect with us on X and LinkedIn.
FORWARD LOOKING STATEMENTS
This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact should be considered forward-looking statements, including, without limitation, statements relating to: nimacimab’s potential as a combination or maintenance therapy by supplement GLP-1 therapies; future clinical development of nimacimab, including the initiation and design of any future clinical trials; expectations regarding the CRC’s review of available Cohort 1 safety data to determine whether safe-to-proceed criteria have been met to initiate enrollment in Cohort 2; the outcome of Skye's evaluation of its manufacturing process improvements, supply-chain options and cost of goods levers; the expected timing for reporting data from the Phase 2a extension study; and the Company’s cash runway. When used herein, words including “anticipate,” “believe,” “can,” “continue,” “could,” “designed,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “might,” “plan,” “planning,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. All forward-looking statements are based upon the Company’s current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important risks and uncertainties, including, without limitation, the initiation and design of any future clinical trials will be impacted by the Company’s capital resources, the Company’s ability to obtain additional sources of capital, program considerations and potentially other factors outside the Company’s control; the potential for additional weight loss after 26 weeks may not ultimately be observed; there is no guarantee that higher dosing of nimacimab will achieve increased efficacy, and likewise it is possible that higher dosing will produce adversely different safety and tolerability results than those observed to date; the Company’s dependence on third parties in connection with product manufacturing; research and preclinical and clinical testing; the Company’s ability to advance, obtain regulatory approval of and ultimately commercialize nimacimab; competitive products or approaches limiting the commercial value of nimacimab; the timing and results of preclinical and clinical trials; the Company’s ability to fund development activities and achieve development goals; the impact of any global pandemics, inflation, supply chain issues, government shutdowns, high interest rates, adverse regulatory changes; the Company’s ability to protect its intellectual property; risks associated with the Company’s common stock and the other important factors discussed under the caption “Risk Factors” in the Company’s filings with the Securities and Exchange Commission, including in its Annual Report on Form 10-K for the year ended December 31, 2025 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, which are accessible on the SEC’s website at www.sec.gov and the Investors section of the Company’s website. Any such forward-looking statements represent management’s estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause the Company’s views to change. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.
| For the Three Months Ended March 31, | |||||||
| 2026 | 2025 | ||||||
| Operating expenses | |||||||
| Research and development | $ | 7,935,680 | $ | 7,197,257 | |||
| General and administrative | 4,738,686 | 4,562,305 | |||||
| Total operating expenses | 12,674,366 | 11,759,562 | |||||
| Operating loss | (12,674,366 | ) | (11,759,562 | ) | |||
| Other (income) expense | |||||||
| Interest expense | 2,199 | 1,452 | |||||
| Interest and other income, net | (169,615 | ) | (619,054 | ) | |||
| Other (income) expense | 2,411 | (40,641 | ) | ||||
| Total other (income) expense, net | (165,005 | ) | (658,243 | ) | |||
| Loss before income taxes | (12,509,361 | ) | (11,101,319 | ) | |||
| Provision for income taxes | — | 2,000 | |||||
| Net loss | $ | (12,509,361 | ) | $ | (11,103,319 | ) | |
| Loss per common share: | |||||||
| Basic | $ | (0.32 | ) | $ | (0.28 | ) | |
| Diluted | $ | (0.32 | ) | $ | (0.28 | ) | |
| Weighted average shares of common stock outstanding used to compute loss per share: | |||||||
| Basic | 39,681,465 | 39,651,888 | |||||
| Diluted | 39,681,465 | 39,651,888 | |||||
| March 31, 2026 | December 31, 2025 | ||||||
| (Unaudited) | |||||||
| ASSETS | |||||||
| Current assets | |||||||
| Cash and cash equivalents | $ | 8,149,015 | $ | 5,882,498 | |||
| Short-term investments | 8,959,614 | 19,854,723 | |||||
| Prepaid expenses | 1,223,534 | 504,890 | |||||
| Other current assets | 234,806 | 852,036 | |||||
| Total current assets | 18,566,969 | 27,094,147 | |||||
| Property and equipment, net | 756,077 | 898,930 | |||||
| Operating lease right-of-use asset | 57,781 | 266,646 | |||||
| Other assets | 35,909 | 53,910 | |||||
| Total assets | $ | 19,416,736 | $ | 28,313,633 | |||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||
| Current liabilities | |||||||
| Accounts payable | $ | 3,936,948 | $ | 2,033,431 | |||
| Accrued payroll liabilities | 234,392 | 1,269,474 | |||||
| Other current liabilities | 3,347,515 | 2,643,840 | |||||
| Estimate for accrued legal contingencies and related expenses | 2,574,759 | 2,069,067 | |||||
| Insurance premium loan payable | 250,338 | — | |||||
| Operating lease liability, current portion | 60,980 | 189,647 | |||||
| Total current liabilities | 10,404,932 | 8,205,459 | |||||
| Non-current liabilities | |||||||
| Operating lease liability, net of current portion | — | 83,999 | |||||
| Total liabilities | 10,404,932 | 8,289,458 | |||||
| Commitments and contingencies | |||||||
| Stockholders’ equity | |||||||
| Preferred stock, | — | — | |||||
| Common stock, | 35,128 | 33,379 | |||||
| Additional paid-in-capital | 208,360,523 | 206,865,282 | |||||
| Accumulated deficit | (199,383,847 | ) | (186,874,486 | ) | |||
| Total stockholders’ equity | 9,011,804 | 20,024,175 | |||||
| Total liabilities and stockholders’ equity | $ | 19,416,736 | $ | 28,313,633 | |||
CONTACTS
Investor Relations
ir@skyebioscience.com
(858) 410-0266
LifeSci Advisors, Mike Moyer
mmoyer@lifesciadvisors.com
(617) 308-4306
Media Inquiries
LifeSci Communications, Michael Fitzhugh
mfitzhugh@lifescicomms.com
(628) 234-3889
